This trial is active, not recruiting.

Conditions implant clinical survival, dental implant bone loss
Treatment spi implant
Phase phase 4
Sponsor Alpha - Bio Tec Ltd.
Start date November 2014
End date May 2017
Trial size 90 participants
Trial identifier NCT02367261, SPI-001


The current prospective clinical study's aim is to determine ABT's SPI implant survival rate, crestal interproximal bone resorption during 24 months post implant insertion and to assimilate the drilling sequence during the clinical use of SPI implants.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Subjects implanted with SPI implant
spi implant
SPI implant - the original spiral implant

Primary Outcomes

Cumulative Survival Rate
time frame: 24 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. Men and women over the age of 18 years who need implantation of 1-4 implants. 2. Patients who are able to understand the requirements of the study, and are willing and able to comply with its instructions and schedules. 3. Patients who had provided written informed consent to participate in the study prior to any study procedure. 4. Patients in general good health in the opinion of the principal investigator as determined by medical history and oral examination. Exclusion Criteria: 1. Immediate loaded implants. 2. Patient requiring bone augmentation 3. Treatment with anticoagulant drugs (INR under 1.8) or bisphosphonates. 4. Treatment with anticonvulsants drugs. 5. Untreated Periodontal disease and inability of the patient to maintain reasonable oral hygiene according to study requirements. 6. Patients with history of alcohol, narcotics or drug abuse. 7. Patients under steroid therapy. 8. Patients receiving radiotherapy, chemotherapy or any other immunosuppressive treatment or who have been administered radiotherapy in the last 5 years. Patients through at anytime received radiotherapy to the head and neck region will be excluded anyway. 9. Metabolic bone disorders and/or bone augmentation. 10. Uncontrolled bleeding disorders such as: hemophilia, thrombocytopenia, granulocytopenia. 11. Degenerative diseases. 12. Osteoradionecrosis. 13. Renal failure. 14. Organ transplant recipients. 15. HIV positive. 16. Malignant diseases. 17. Diseases that compromise the immune system. 18. Unbalanced diabetes mellitus. (HbA1c above 6.5) 19. Psychotic diseases. 20. Hypersensitivity to one of the components of the implant in general and titanium in particular. 21. Women who are pregnant or lactating. 22. Lack of patient cooperation. 23. Uncontrolled endocrine diseases. 24. Any systemic condition that is unbalanced and therefore precludes surgical procedures. 25. Parafunctional habits.- e.g Bruxism. 26. Temporomandibular joint disease. 27. Various pathologies of the oral mucosa for example: Benign mucous pemphigoid, desquamative ginigivitis, erosive lichen planus ,malignancy of oral cavity, bolus erosive diseases of the oral mucosa. 28. Flapless procedures.

Additional Information

Official title An Open, Prospective, Multi-center Study to Evaluate Bone Loss, the Survival Rate of SPI Implant System and Implant Stability Over a 24 Months, in Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol.
Principal investigator Yi Man, Dr
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by Alpha - Bio Tec Ltd..